Lecture Summary - CARD Trial: Safety and Efficacy of Cabazitaxel in …

Dana-Farber Cancer Institute

A. Choudhury

CARD Trial: Safety and Efficacy of Cabazitaxel in mCRPC & Age Subgro…

Dana-Farber Cancer Institute

A. Choudhury

Challenging Genitourinary Tumors: What’s New in Prostate Cancer

Penn Medicine Abramson Cancer Center

V. Narayan

Genetics/Genomics in Prostate Cancer

Stanford Medicine

M. Cooperberg

Stanford Medicine Historical Landscape of Testing: Blood-Based Diagn…

Stanford Medicine

J. Leppert

ASCO 2022 Updates on Molecular Based Imaging for Prostate Cancer: Re…

Nebraska Oncology Society

T. Hope

ASCO 2022 on the Latest Developments in mHSPC and mCRPC

ecancer

H. Payne, K. Chi, K. Miller, L. Krabbe

New Therapeutic Discoveries and Mechanisms for CRPC

Masonic Cancer Center, University of Minnesota

K. Kelly

Prostate Cancer Imaging Updates: What, Why, and When

Martin Allen-Auerbach

Cabazitaxel Activity in Men With mCRPC With & Without DNA Damage Rep…

Elena Castro

Finding the Optimal Sequence for mCRPC

Benjamin L. Maughan

Second Line Therapy Options in mCRPC

Karam Al-Issa

Patient Preference Between Cabazitaxel and Docetaxel for 1L Chemothe…

Giulia Baciarello